Janssen Diagnostics was established in February 2012 within Janssen Pharmaceuticals R&D, bringing together personnel with diverse healthcare experiences, skills and knowledge across diagnostics, pharmaceuticals and health information technologies. We are a global company, based in Beerse, Belgium and Raritan, New Jersey, United States, and employ around 150 professionals from R&D to commercial roles.
Our goal is to think beyond drug treatment and grow as a true solution provider. The Janssen legacy of excellence in Infectious Diseases, Oncology, Neuroscience, Cardiovascular Diseases and Immunology will continue to drive innovation in the fields of Diagnostics Solutions and Health Information Technology, enabling us to reach our goal: to develop care solutions that cater to each individual’s needs.
Our focus is on initiatives that will develop diagnostics linked to the use of a drug within its approved label (companion diagnostics) and diagnostics or information tools that support disease management, around the use of a drug or drug regimens (complementary diagnostics). Our interest in health information tools support real-world data access and insights to help better manage individual patients and/or cohorts of patients.
Recognizing the diversity and complexity of advancing personalized healthcare solutions, our business model is predominantly partnership driven to ensure wide access to our diagnostic solutions globally. Consequently, we continuously look for opportunities to discuss potential areas of common interest with researchers, academia and industry partners.
Janssen Diagnostics, LLC is committed to supporting the HIV/AIDS community and continues to work as a partner with healthcare professionals in this therapeutic area as it did as Virco Lab, Inc. for more than 15 years. Janssen Diagnostics, LLC continues to listen to the challenges and opportunities that clinicians and other healthcare professionals have encountered in treating HIV/AIDS in an effort to consistently enhance the products and services the company provides to better meet the needs of the HIV/AIDS community.
In December 2009, Virco (now Janssen Diagnostics) acquired LAB TRACKER™ HIV, a customizable electronic health record (EHR) from Ground Zero Software. The product has been completely redesigned using insights from healthcare professionals immersed in HIV care to meet today and tomorrow's clinical needs.. AVIGA™ and AVIGA REPORTER™ are natural extensions of the Janssen Diagnostics, LLC product portfolio and commitment to its core mission and values: to support HIV healthcare professionals with integrated information from multiple sources to effectively manage their patients living with HIV/AIDS.
EHRs offer several advantages for general patient management and are particularly useful for complex diseases, such as HIV, which often have a multitude of test results, analyses, and co-morbidities. The acquisition of LAB TRACKER™ HIV was a natural extension of our overall product line and lends to the Janssen Diagnostics, LLC commitment to save and improve patients' lives, through the integration and delivery of differentiating diagnostic and health IT solutions into world-class personalized disease management.
No. While AVIGA™ maintains many of the core functions and most desirable features that LAB TRACKER™ HIV users valued most, it has been totally redesigned to meet current standards for electronic health records. It includes a more powerful querying and reporting function designed to address the specific needs and challenges of the HIV/AIDS and Infectious Disease communities.
Yes. AVIGA™ is also completely suitable as a general purpose EHR for use in the ambulatory care setting; yet it retains functionalities uniquely required by healthcare professionals involved in HIV/AIDS care.
AVIGA EHR is working towards meeting the 2014 certification criteria adopted by the Secretary of Health and Human Services. The 2014 Edition criteria support both Stage 1 and 2 meaningful use measures required to qualify eligible providers and hospitals for funding under the American Recovery and Reinvestment Act (ARRA).
The Stage 1 criteria of Meaningful Use required users adopt and follow a core set of 15 measures, and from a set "menu" of 10 additional objectives, users were required to select and implement five additional objectives. A detailed list of Stage 1 measures can be found here. The AVIGA™ electronic health record (EHR) was fully certified as an EHR for use in ambulatory care settings by the Drummond Group Inc., an ONC-ATCB1 provider, to meet the meaningful use (MU) Stage 1 criteria for EHRs. However, as of January 1, 2014, to be MU certified, software must meet the requirements of Stage 1 and Stage 2. Stage 2 requires Eligible Professionals to achieve 17 core items, along with a menu set of six, of which they are required to only choose three. A list of the Stage 2 requirements can be found here, and a comparison of Stage 1 and Stage 2 can be accessed here.
We are working on securing 2014 certification for the AVIGA™ EHR and will update the site once this has been obtained.
No. Although AVIGA REPORTER™ is not certified for Meaningful Use, the analytics and reporting functions simplify the research/reporting process (e.g. Ryan White reporting requirements, Comprehensive Care Centers, etc.) and help healthcare professionals concentrate on patient care, not paperwork.
As new requirements for reporting become available, Janssen Diagnostics, LLC will consider updating the HIV reports in AVIGA™ and AVIGA REPORTER™.
Yes. We provide several individualized training options to meet the needs of your site. Please contact Customer Support for details.
As part of the initial site configuration process, your existing data will be evaluated, and a plan created to transfer your current system to AVIGA™ or AVIGA REPORTER™. Every situation is different, so please contact Customer Support with any questions you may have.
Yes. We have conversion utilities available to help with the migration of your CAREWare™ database to AVIGA™ or AVIGA REPORTER™. Please contact Customer Support for further details. CAREWare™ is a trademark of Jeff Murray's Programming Shop, Inc. and is not affiliated with, associated with, or a sponsor of the AVIGA™ or AVIGA REPORTER™ software.
For the most up-to-date and accurate product pricing, please contact your Janssen Diagnostics, LLC Sales Representative. To have a Sales Representative contact you, please call 888-224-4230, and then press 3 for Product Sales. You can also email your support questions to AVIGAehr.Support@its.jnj.com.
Our toll-free phone line and email support are available to help answer your questions. To reach support by phone, dial 888-224-4230, and then press 2 for Customer Support. You can also email your support questions to AVIGAehr.Support@its.jnj.com.
DISCLAIMER: THE INFORMATION CONTAINED IN THIS WEBSITE IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND REPRESENTS NO STATEMENT, PROMISE OR GUARANTEE BY JANSSEN DIAGNOSTICS, LLC CONCERNING RECEIPT OR PAYMENT OF GOVERNMENT INCENTIVES. JANSSEN DIAGNOSTICS, LLC STRONGLY URGES THAT YOU CONSULT WITH YOUR COUNSEL FOR ADVICE ON INCENTIVE ELIGIBILITY.
On February 2nd, 2012, Virco Lab, Inc.
changed its legal name to Janssen Diagnostics, Inc.
Our website is in the process of being updated to
reflect these name changes.